日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study

阿柏西普 2 毫克生物类似药(阿柏西普-ayyh,Pavblu):临床安全性经验——APEX 安全性研究

Sharma, Ashish; Khanani, Arshad M; Eichenbaum, David; Boyer, David; Shaer, Alexander; Ortiz, Trisha; Sulahria, Humza; Flores, Allyza; Regillo, Carl

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

PULSAR 研究 48 周结果的简要概述,该研究旨在调查新剂量阿柏西普治疗湿性年龄相关性黄斑变性的疗效和安全性。

Lanzetta, Paolo; Korobelnik, Jean-François; Heier, Jeffrey S; Leal, Sergio; Holz, Frank G; Clark, William Lloyd; Eichenbaum, David; Iida, Tomohiro; Sun, Xiaodong; Berliner, Alyson J; Schulze, Andrea; Schmelter, Thomas; Schmidt-Ott, Ursula; Zhang, Xin; Vitti, Robert; Chu, Karen W; Reed, Kimberly; Rao, Rohini; Bhore, Rafia; Cheng, Yenchieh; Wong, Tien Y

Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series

阿柏西普 8 mg 治疗新生血管性 AMD 的真实世界疗效和安全性:病例系列研究

Sambhara, Deepak; Vakharia, Priya; Eichenbaum, David A

Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study

生物类似药雷珠单抗(Ranieyes)在真实世界中的安全性和有效性:BRESER 研究

Sharma, Ashish; Holz, Frank G; Kumar, Nilesh; Sarraf, David; Ayachit, Seemantini; Mishra, Chitaranjan; Tufail, Adnan; Chakraborty, Debdulal; Rachitskaya, Aleksandra; Eichenbaum, David; Banker, Alay; Parachuri, Nikulaa; Kumar, Ashish; Loewenstein, Anat; Bandello, Francesco; Wakabayashi, Taku; Woo, Se Joon; Kuppermann, Baruch D

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy

玻璃体内注射Pegcetacoplan与Avacincaptad Pegol治疗地图状萎缩患者的疗效比较

Hahn, Paul; Eichenbaum, David; Dhoot, Dilsher S; Wykoff, Charles C; Klufas, Michael A; Intorcia, Michele; Jones, Daniel; Sarda, Sujata P; Bobbili, Priyanka; Chang, Rose; Catillon, Maryaline; Xu, Chunyi; Sarathy, Kirthana; Duh, Mei Sheng; Baumal, Caroline R; Chaudhary, Varun

Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices

视网膜诊疗中抗VEGF药物的预先授权

Dang, Sabin; Parke, D Wilkin; Sodhi, Guneet S; Eichenbaum, David; Nielsen, Jared; Danzig, Carl; Lalwani, Geeta; Moinfar, Nader; London, Nikolas; Kimura, Alan; Jumper, J Michael; Lord, Ken; Sheth, Veeral; Pieramici, Dante; Orlin, Anton; Madson, Allison; Horton, Monica; Blim, Jill; Cao, Jessica A; Thompson, John; Khanna, Saira; Wykoff, Charles C; Shah, Ankoor R

Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration

DAVIO I期试验:EYP-1901生物可降解缓释沃罗拉尼植入剂治疗湿性年龄相关性黄斑变性患者

Patel, Sunil; Storey, Philip P; Barakat, Mark R; Hershberger, Vrinda; Bridges, William Z Jr; Eichenbaum, David A; Lally, David R; Boyer, David S; Bakri, Sophie J; Roy, Monica; Paggiarino, Dario A

Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review

血管内皮生长因子C和D信号通路作为治疗新生血管性年龄相关性黄斑变性的潜在靶点:一篇叙述性综述

Leitch, Ian M; Gerometta, Michael; Eichenbaum, David; Finger, Robert P; Steinle, Nathan C; Baldwin, Megan E

Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients.

氟轻松丙酮 0.18 毫克植入剂治疗非感染性葡萄膜炎引起的复发性炎症:15 例患者的病例系列

Sisk Robert A, Kiernan Daniel F, Almeida David, Kolomeyer Anton M, Eichenbaum David, Kitchens John W

Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial

Brolucizumab治疗糖尿病性黄斑水肿的疗效和安全性:KINGFISHER随机临床试验

Singh, Rishi P; Barakat, Mark R; Ip, Michael S; Wykoff, Charles C; Eichenbaum, David A; Joshi, Sunir; Warrow, David; Sheth, Veeral S; Stefanickova, Jana; Kim, Yong Soo; He, Fanyin; Cho, Ga Eun; Wang, Yuhua; Emanuelli, Andrés